ArriVent Biopharma Appoints New CMO, Elects Director
Ticker: AVBP · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $235,000, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
ArriVent Biopharma shakes up leadership with a new CMO and board member.
AI Summary
ArriVent Biopharma, Inc. announced on April 20, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or leadership focus, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- ArriVent Biopharma, Inc. (company) — Registrant
- Dr. Jonathan F. Miller (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
FAQ
What is the effective date of Dr. Jonathan F. Miller's appointment as Chief Medical Officer?
The filing indicates the earliest event reported was April 20, 2024, suggesting this is the effective date or around it.
What is the background or relevant experience of Ms. Sarah E. Kelly?
The provided text does not detail Ms. Sarah E. Kelly's background or relevant experience.
What specific compensatory arrangements were disclosed for the named executive officers?
The filing mentions the disclosure of compensatory arrangements but does not specify the details within the provided text.
What is ArriVent Biopharma's primary business sector?
ArriVent Biopharma, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
Where is ArriVent Biopharma, Inc. headquartered?
ArriVent Biopharma, Inc. is headquartered at 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073.
Filing Stats: 1,030 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-04-22 16:10:00
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
- $235,000 — Date"), with a Grant Date fair value of $235,000 (the "Option"). The Option will vest on
- $45,000 — d to receive an annual cash retainer of $45,000 for her service as a non-employee direc
Filing Documents
- tm2412347d1_8k.htm (8-K) — 30KB
- tm2412347d1_exx99-1.htm (EX-99.1) — 9KB
- tm2412347d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-049988.txt ( ) — 221KB
- avbp-20240420.xsd (EX-101.SCH) — 3KB
- avbp-20240420_lab.xml (EX-101.LAB) — 33KB
- avbp-20240420_pre.xml (EX-101.PRE) — 22KB
- tm2412347d1_8k_htm.xml (XML) — 4KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 20, 2024, the Board of Directors (the "Board") of ArriVent BioPharma, Inc. (the "Company") appointed Kristine Peterson to the Board, effective immediately (the "Effective Date"). Ms. Peterson will serve as a Class III Director until the Company's 2027 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation, retirement or removal. Ms. Peterson, age 64, most recently served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms. Peterson was Company Group Chair of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics manufacturing for oncology, immunology and cell therapy, and was Executive Vice President of Pharmaceutical Group Strategic Marketing from 2004 to 2006. Previously, she served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles across multiple disease areas, including running their cardiovascular and metabolics business unit. Ms. Peterson has served on the boards of directors of Enanta Pharmaceuticals since September 2017 and Immunocore Holdings since November 2017. She previously served on the boards of directors for ImmunoGen, Inc., Amarin Corporation plc, EyePoint Pharmaceuticals and Paratek Pharmaceuticals. Additionally, she previously served as a senior advisor to the Healthcare Businesswomen's Association and a Member of the Biotechnology Industry Organization (BIO) Board. Ms. Peterson has a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign. The Board has affirmatively determined that Ms. Peterson is an indepe
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung, MBA Winston Kung, MBA Chief Financial Officer and Treasurer Date: April 22 , 2024